Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02KKA
|
||||
Former ID |
DCL000569
|
||||
Drug Name |
MK-1775
|
||||
Drug Type |
Small molecular drug
|
||||
Company |
Merck
|
||||
Structure |
Download2D MOL |
||||
Formula |
C27H32N8O2
|
||||
InChI |
InChI=1S/C27H32N8O2/c1-5-13-34-25(36)21-18-28-26(29-19-9-11-20(12-10-19)33-16-14-32(4)15-17-33)31-24(21)35(34)23-8-6-7-22(30-23)27(2,3)37/h5-12,18,37H,1,13-17H2,2-4H3,(H,28,29,31)
|
||||
InChIKey |
BKWJAKQVGHWELA-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
50087297, 57153446, 103905025, 119526878, 123055428, 124757316, 125164120, 134339129, 136340195, 136348241, 136367536, 137276027, 140608871, 144116226, 152258293, 160647132, 162012024, 162037646, 162127566, 162202673, 163643009, 163907976, 164042069, 172087065, 176251781, 177748702, 184823454, 198966582, 219813764, 223366035, 223375310, 223623577, 223705090, 227708523, 242060384, 242514641, 244576507, 249859269, 250211323, 252065946, 252110173, 252160193, 252215807, 252442192, 252451627
|
||||
ChEBI ID |
ChEBI:45713
|
||||
Target and Pathway | |||||
Target(s) | Wee1-like protein kinase | Target Info | Inhibitor | [537429], [549718] | |
KEGG Pathway | Cell cycle | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
Pathway Interaction Database | PLK1 signaling events | ||||
Reactome | Polo-like kinase mediated events | ||||
Cyclin E associated events during G1/S transition | |||||
Cyclin A/B1 associated events during G2/M transition | |||||
G2/M DNA replication checkpoint | |||||
Cyclin A:Cdk2-associated events at S phase entry | |||||
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | |||||
Factors involved in megakaryocyte development and platelet production | |||||
References | |||||
Ref 531656 | Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther. 2011 Dec;10(12):2405-14. | ||||
Ref 542678 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7702). | ||||
Ref 537429 | Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer. 2009 Jun 8;8:34. | ||||
Ref 549718 | A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.